Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus
Carregando...
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
DOVE MEDICAL PRESS LTD
Autores
TAVARES, Rita Chelly Felix
FELDNER, Ana Cristina de Castro Amaral
CARVALHO-FILHO, Roberto Jose
SANTANA, Rtibia Anita Ferraz
CASTRO, Vanessa Fusco Duarte de
DASTOLI, Gregorio Tadeu Fernando
LIMA, Juliana Custadio
FERRA, Maria Lucia Cardoso Gomes
Citação
INFECTION AND DRUG RESISTANCE, v.11, p.1993-2000, 2018
Resumo
Background: Direct-acting antiviral agents (DAAs) permit the use of interferon (IFN)-free regimens to treat hepatitis C (HCV) in patients with chronic kidney disease (CKD) on hemodialysis (HD) or renal transplant (RTx) recipients, with excellent response rates and safety. However, the occurrence of basal or therapy-induced resistance-associated substitutions (RASs) to DAAs can result in treatment failure. The aim of this study was to estimate the prevalence of RASs to NS3A, NS5A and NS5B inhibitors, and particularly the Q80K polymorphism, in CKD patients on HD and RTx recipients infected with HCV. Patients and methods: HD and RTx patients infected with HCV-genotype 1 (GT1) were subjected to sequencing of the NS3, NS5A and NS5B regions. Results: Direct sequencing of NS3 protease, NS5A and NS5B was performed in 76 patients (HD, n=37; RTx, n=39). The overall prevalence of RASs was 38.2%, but only 5.3% of the patients had mutations in more than one region. Substitutions were detected in NS3A (17.8%), NS5A (21.9%) and NS5B (8.4%). Q80K was detected in 1.5 % of the patients. Highly inhibitory RASs were uncommon (L31M, 2.6%; L159F+C316N, 2.6%). RASs were more prevalent in HCV-GT1a (42.9%) than in HCV-GT1b (32.4%), P=0.35. RASs were detected in 52.4% of treatment-naive patients and 27.8% of peg-IFN/ribavirin-experienced patients (P=0.12). The presence of RASs was associated with time of RTx (P=0.01). Conclusion: The Q80K polymorphism was uncommon in our sample of HD and RTx patients. Despite the high prevalence of naturally occurring RASs, most of the substitutions detected were associated with a low level of resistance to DAAs.
Palavras-chave
HCV, treatment, DAA resistance, hepatitis
Referências
- Ahmed A, 2015, VIRUSES-BASEL, V7, P6716, DOI 10.3390/v7122968
- Patino-Galindo JA, 2016, ANTIMICROB AGENTS CH, V60, P2402, DOI 10.1128/AAC.02776-15
- Bartels DJ, 2008, J INFECT DIS, V198, P800, DOI 10.1086/591141
- Bhamidimarri KR, 2016, J HEPATOL, V65, P7, DOI 10.1016/j.jhep.2016.04.003
- Brennan BJ, 2013, ANTIMICROB AGENTS CH, V57, P6097, DOI 10.1128/AAC.00608-13
- Buti M, 2015, J HEPATOL, V63, P1511, DOI 10.1016/j.jhep.2015.08.010
- da Silva RA, 2018, J MED VIROL, V90, P537, DOI 10.1002/jmv.24976
- de Carvalho IMVG, 2014, J MED VIROL, V86, P1714, DOI 10.1002/jmv.24015
- Deng HH, 2018, J MED VIROL, V90, P1246, DOI 10.1002/jmv.25078
- Etik DO, 2015, WORLD J HEPATOL, V7, P885, DOI 10.4254/wjh.v7.i6.885
- Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
- Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
- Fabrizi F, 2007, J VIRAL HEPATITIS, V14, P697, DOI 10.1111/1365-2893.2007.00868.x
- Fabrizi F, 2014, J VIRAL HEPATITIS, V21, P314, DOI 10.1111/jvh.12148
- Fabrizi F, 2017, INT J ARTIF ORGANS, V40, P531, DOI 10.5301/ijao.5000613
- Fridell RA, 2011, HEPATOLOGY, V54, P1924, DOI 10.1002/hep.24594
- Halfon P, 2011, J HEPATOL, V55, P192, DOI 10.1016/j.jhep.2011.01.011
- Kamar N, 2016, AM J TRANSPLANT, V16, P1474, DOI 10.1111/ajt.13518
- Khedmat H, 2014, SAUDI J KIDNEY DIS T, V25, P1, DOI 10.4103/1319-2442.124455
- Kidney Disease: Improving Global Outcomes (KDIGO), 2017, KDIGO CLIN PRACT GUI
- Kieffer TL, 2014, CURR OPIN VIROL, V8, P16, DOI 10.1016/j.coviro.2014.04.008
- Kim E, 2011, ANN HEPATOL, V10, P5
- Kuntzen T, 2008, HEPATOLOGY, V48, P1769, DOI 10.1002/hep.22549
- Lontok E, 2015, HEPATOLOGY, V62, P1623, DOI 10.1002/hep.27934
- Marinaki S, 2015, WORLD J HEPATOL, V7, P548, DOI 10.4254/wjh.v7.i3.548
- McCloskey RM, 2015, J INFECT DIS, V211, P1288, DOI 10.1093/infdis/jiu613
- Morales JM, 2015, NAT REV NEPHROL, V11, P172, DOI 10.1038/nrneph.2015.5
- Moreira RC, 2018, ARCH VIROL
- Nettles RE, 2011, HEPATOLOGY, V54, P1956, DOI 10.1002/hep.24609
- Noble CF, 2017, ARCH VIROL, V162, P165, DOI 10.1007/s00705-016-3094-2
- Paolucci S, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-355
- Paolucci S, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-245
- Pawlotsky JM, 2016, GASTROENTEROLOGY, V151, P70, DOI 10.1053/j.gastro.2016.04.003
- Pawlotsky JM, 2013, J HEPATOL, V59, P375, DOI 10.1016/j.jhep.2013.03.030
- Peres-da-Silva A, 2017, ANTIVIR THER, V22, P447, DOI 10.3851/IMP3131
- Peres-da-Silva A, 2015, J ANTIMICROB CHEMOTH, V70, P726, DOI 10.1093/jac/dku462
- Peres-da-Silva A, 2012, MEM I OSWALDO CRUZ, V107, P254, DOI 10.1590/S0074-02762012000200016
- Peres-da-Silva A, 2010, ARCH VIROL, V155, P807, DOI 10.1007/s00705-010-0642-z
- Perez RM, 2003, J MED VIROL, V69, P489, DOI 10.1002/jmv.10336
- Poveda E, 2014, ANTIVIR RES, V108, P181, DOI 10.1016/j.antiviral.2014.05.015
- Roth D, 2015, LANCET, V386, P1537, DOI 10.1016/S0140-6736(15)00349-9
- Sandres-Saune K, 2003, J VIROL METHODS, V109, P187, DOI 10.1016/S0166-0934(03)00070-3
- Sanger W G, 1977, Nebr Med J, V62, P422
- Sarrazin C, 2016, J HEPATOL, V64, P486, DOI 10.1016/j.jhep.2015.09.011
- Sarrazin C, 2015, ANTIVIR RES, V116, P10, DOI 10.1016/j.antiviral.2015.01.003
- Sawinski D, 2016, AM J TRANSPLANT, V16, P1588, DOI 10.1111/ajt.13620
- Sede MM, 2015, INT J ANTIMICROB AG, V46, P219, DOI 10.1016/j.ijantimicag.2015.04.011
- Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
- Singh T, 2016, LIVER INT, V36, P802, DOI 10.1111/liv.13078
- Smith DB, 2014, HEPATOLOGY, V59, P318, DOI 10.1002/hep.26744
- Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
- Welsch Christoph, 2014, Drug Discov Today Technol, V11, P19, DOI 10.1016/j.ddtec.2013.12.003
- Wiegand J, 2014, ALIMENT PHARM THER, V39, P1342, DOI [10.1111/apt.12748, 10.1111/apt.12738]